Abstract 116P
Background
Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer. The prognostic role of Fibrous sheath interacting protein 1 (FSIP1) in LUAD remains unclear. Thus, this study aims to identify and validate the prognostic value of FSIP1 in LUAD and explore its molecular functions.
Methods
Single-cell RNA sequencing (scRNA-seq) data of LUAD patients were collected from Gene Expression Omnibus (GEO) database, the major cell types were identified based on known markers. Additionally, the expression of FSIP1 was detected in 180 LUAD samples, Kaplan-Meier (KM) analysis of high- and low-expression patients was conducted. Univariate and multivariate Cox regression analyses were utilized to assess the prognostic ability of FSIP1. Then, FSIP1-silenced human LUAD cell lines were constructed, and the functions of FSIP1 were explored. Finally, immune infiltration analysis was performed in LUAD patients.
Results
In this study, we identified LUAD FSIP1+ cancer cells by using scRNA-seq data from GEO database. Additionally, we investigated the protein level and prognostic value of FSIP1 in 98 LUAD patients using Tissue Microarray. Compared with the adjacent, FSIP1 was higher expressed in LUAD tissues. KM analysis revealed that the 5-year OS rate to be 30% to 59% (FSIP1High vs FSIP1Low) in Tissue Microarray. Univariate and multivariate COX regression showed that FSIP1 should be an independent factor in poor prognosis. The receiver operating characteristic curve (ROC) and time-ROC curve both indicated that FSIP1 had a good performance in prognostic model. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that FSIP1 was associated with migration. Migration assay and Western blotting showed that FSIP1 influenced cell migration and PI3K/AKT pathway. FSIP1 could influence the immune cell infiltration in lung adenocarcinoma patients.
Conclusions
This study verified that FSIP1 could serve as a valuable prognostic biomarker in LUAD and analyzed its impact on the disease and its association with the immune infiltration. The findings of this research provide valuable insights into the understanding of LUAD and could potentially lead to the development of new treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Tumorspheres cultured from circulating cancer stem cells overexpress the innate checkpoint CD47 in breast cancer patients
Presenter: Monika Pizon
Session: Poster session 08
Resources:
Abstract
164P - A spatially informed transcriptomic model to forecast early resistance to front-line osimertinib in advanced EGFR-mutant NSCLC
Presenter: Jon Zugazagoitia
Session: Poster session 08
165P - Consistency analysis of c-Met protein expression over time in patients with non-squamous non-small cell lung cancer
Presenter: Alexis Cortot
Session: Poster session 08
166P - Integrative multi-omics refine molecular diagnostics in non-small cell lung cancer
Presenter: Li Ren Kong
Session: Poster session 08
167P - Tumor-immune spatial interactions on NSCLC H&E slide images predicts immunotherapy response: Preliminary external validation
Presenter: Liam Il-Young Chung
Session: Poster session 08
168P - Biosimulation coupled with personalized tumor microenvironment (TME) modeling predicts response to immunotherapy treatment in NSCLC patients
Presenter: Himanshu Grover
Session: Poster session 08
169P - Analysis of tumor immune microenvironment with mIHC in Chinese non-small cell lung cancer
Presenter: Hao Wu
Session: Poster session 08
170P - Clinical presentations and prognosis of HER2-low breast cancer in Taiwan
Presenter: Grace Chen
Session: Poster session 08
171P - A computational pathology collagen signature predictive of tamoxifen benefit in ductal carcinoma in situ: Results from a cohort within the UK/ANZ DCIS randomized trial
Presenter: Arpit Aggarwal
Session: Poster session 08
172P - HER2 expression across solid tumors and real-world implications for use of fam-trastuzumab deruxtecan-nxki (T-Dxd)
Presenter: Ahmed Ismail
Session: Poster session 08